WallStreetZenWallStreetZen

NASDAQ: DMAC
Diamedica Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DMAC

Based on 3 analysts offering 12 month price targets for Diamedica Therapeutics Inc

Min Forecast
$11.00+90.97%
Avg Forecast
$12.33+114.11%
Max Forecast
$14.00+143.06%

Should I buy or sell DMAC stock?

Based on 3 analysts offering ratings for Diamedica Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DMAC's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DMAC as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their DMAC stock forecasts and price targets.

DMAC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-15
lockedlocked$00.00+00.00%2025-07-18
lockedlocked$00.00+00.00%2025-07-18

1 of 1

Forecast return on equity

Is DMAC forecast to generate an efficient return?

Company
-81.8%
Industry
126.43%
Market
-47.44%
DMAC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DMAC forecast to generate an efficient return on assets?

Company
-70.63%
Industry
47.5%
DMAC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DMAC earnings per share forecast

What is DMAC's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.72
Avg 2 year Forecast
-$0.90
Avg 3 year Forecast
-$0.89

DMAC revenue forecast

What is DMAC's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$11.2M
Avg 2 year Forecast
$42.1M
Avg 3 year Forecast
$83.8M

DMAC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DMAC$5.76$12.33+114.11%Strong Buy
AVIR$3.53$6.00+69.97%Hold
RNAC$11.28$39.33+248.70%Buy
LCTX$1.28$4.67+264.61%Strong Buy
NGNE$20.45$32.20+57.46%Buy
View Top Biotech Stocks

Diamedica Therapeutics Stock Forecast FAQ

Is Diamedica Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: DMAC) stock is to Strong Buy DMAC stock.

Out of 3 analysts, 1 (33.33%) are recommending DMAC as a Strong Buy, 2 (66.67%) are recommending DMAC as a Buy, 0 (0%) are recommending DMAC as a Hold, 0 (0%) are recommending DMAC as a Sell, and 0 (0%) are recommending DMAC as a Strong Sell.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.

What is DMAC's earnings growth forecast for 2025-2027?

(NASDAQ: DMAC) Diamedica Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.24%.

Diamedica Therapeutics's earnings in 2025 is -$29,560,000.On average, 1 Wall Street analyst forecast DMAC's earnings for 2025 to be -$37,216,017, with the lowest DMAC earnings forecast at -$37,216,017, and the highest DMAC earnings forecast at -$37,216,017. On average, 1 Wall Street analyst forecast DMAC's earnings for 2026 to be -$46,520,022, with the lowest DMAC earnings forecast at -$46,520,022, and the highest DMAC earnings forecast at -$46,520,022.

In 2027, DMAC is forecast to generate -$46,003,133 in earnings, with the lowest earnings forecast at -$46,003,133 and the highest earnings forecast at -$46,003,133.

What is DMAC's revenue growth forecast for 2027-2029?

(NASDAQ: DMAC) Diamedica Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.94%.

Diamedica Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast DMAC's revenue for 2027 to be $576,331,380, with the lowest DMAC revenue forecast at $576,331,380, and the highest DMAC revenue forecast at $576,331,380. On average, 1 Wall Street analysts forecast DMAC's revenue for 2028 to be $2,178,170,794, with the lowest DMAC revenue forecast at $2,178,170,794, and the highest DMAC revenue forecast at $2,178,170,794.

In 2029, DMAC is forecast to generate $4,331,014,020 in revenue, with the lowest revenue forecast at $4,331,014,020 and the highest revenue forecast at $4,331,014,020.

What is DMAC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: DMAC) forecast ROA is -70.63%, which is lower than the forecast US Biotechnology industry average of 47.5%.

What is DMAC's Price Target?

According to 3 Wall Street analysts that have issued a 1 year DMAC price target, the average DMAC price target is $12.33, with the highest DMAC stock price forecast at $14.00 and the lowest DMAC stock price forecast at $11.00.

On average, Wall Street analysts predict that Diamedica Therapeutics's share price could reach $12.33 by Aug 15, 2026. The average Diamedica Therapeutics stock price prediction forecasts a potential upside of 114.11% from the current DMAC share price of $5.76.

What is DMAC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: DMAC) Diamedica Therapeutics's current Earnings Per Share (EPS) is -$0.69. On average, analysts forecast that DMAC's EPS will be -$0.72 for 2025, with the lowest EPS forecast at -$0.72, and the highest EPS forecast at -$0.72. On average, analysts forecast that DMAC's EPS will be -$0.90 for 2026, with the lowest EPS forecast at -$0.90, and the highest EPS forecast at -$0.90. In 2027, DMAC's EPS is forecast to hit -$0.89 (min: -$0.89, max: -$0.89).

What is DMAC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: DMAC) forecast ROE is -81.8%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.